Case Study

Variant Translocation Partners of the Anaplastic Lymphoma Kinase (*ALK*) Gene in Two Cases of Anaplastic Large Cell Lymphoma, Identified by Inverse cDNA Polymerase Chain Reaction

Kayo Takeoka,¹⁾ Atsuko Okumura,¹⁾ Gen Honjo,²⁾ and Hitoshi Ohno^{1,3)}

In anaplastic large cell lymphoma (ALCL), the anaplastic lymphoma kinase (*ALK*) gene is rearranged with diverse partners due to variant translocations/inversions. Case 1 was a 39-year-old man who developed multiple tumors in the mediastinum, psoas muscle, lung, and lymph nodes. A biopsy specimen of the inguinal node was effaced by large tumor cells expressing CD30, epithelial membrane antigen, and cytoplasmic ALK, which led to a diagnosis of ALK⁺ ALCL. Case 2 was a 51-year-old man who was initially diagnosed with undifferentiated carcinoma. He developed multiple skin tumors eight years after his initial presentation, and was finally diagnosed with ALK⁺ ALCL. He died of therapy-related acute myeloid leukemia. G-banding and fluorescence *in situ* hybridization using an *ALK* break-apart probe revealed the rearrangement of *ALK* and suggested variant translocation in both cases. We applied an inverse cDNA polymerase chain reaction (PCR) strategy to identify the partner of *ALK*. Nucleotide sequencing of the PCR products and a database search revealed that the sequences of *ATIC* in case 1 and *TRAF1* in case 2 appeared to follow those of *ALK*. We subsequently confirmed *ATIC-ALK* and *TRAF1-ALK* fusions by reverse transcriptase PCR and nucleotide sequencing. We successfully determined the partner gene of *ALK* in two cases of ALK⁺ ALCL. *ATIC* is the second most common partner of variant *ALK* rearrangements, while the *TRAF1-ALK* fusion gene was first reported in 2013, and this is the second reported case of ALK⁺ ALCL carrying *TRAF1-ALK*. [*J Clin Exp Hematop* 54(3): 225-235, 2014]

Keywords: anaplastic large cell lymphoma, FISH, inverse cDNA PCR, *ATIC* gene, *TRAF1* gene

INTRODUCTION

Anaplastic large cell lymphoma (ALCL) that is positive for the expression of ALK (ALK⁺) is a well-defined subtype of peripheral T-cell lymphoma.^{1,2} The disease is characterized by the anaplastic morphology of lymphoma cells, expression of CD30 on their cell surface, and chromosomal rearrangement involving the *ALK* gene locus at 2p23. The majority of cases carry t(2;5)(p23;q35), which leads to the generation of a fusion gene with the nucleophosmin (*NPM*) gene at 5q35, encoding the oncogenic kinase NPM-ALK chimeric protein. However, rearrangements involve diverse partner genes and/or chromosomal loci in the minority of

cases.¹⁻³ Over 20 genes and/or recurrent chromosomal rearrangements have been identified as partners of *ALK*.³ In contrast to the NPM-ALK fusion protein, which shows both the nuclear and the cytoplasmic expression of ALK, the subcellular localization of other fusion proteins varies depending upon each rearrangement.^{1,2}

The 5' RACE (rapid amplification of cDNA ends) protocol has been used to clone an unknown partner that fuses to a known gene from an mRNA template.⁴ In a very recent case report on ALK⁺ ALCL, deep RNA sequencing successfully identified the gene for tumor necrosis factor (TNF) receptor-associated factor 1 (*TRAF1*) as the partner of *ALK*.⁵ We herein present the clinical, histopathological, and cytogenetic features of two cases of ALK⁺ ALCL. To identify the partner genes of *ALK*, we applied an inverse cDNA polymerase chain reaction (PCR)-based technique, which allowed the amplification of unknown sequences enclosed by known *ALK* sequences.

Received: July 18, 2014

Revised : August 28, 2014

Accepted: September 17, 2014

¹⁾Tenri Institute of Medical Research, Tenri, Japan

Departments of ²⁾Diagnostic Pathology and ³⁾Hematology, Tenri Hospital, Tenri, Japan

Corresponding author: Kayo Takeoka, Tenri Institute of Medical Research, 200 Mishima, Tenri, Nara 632-8552, Japan

e-mail: takeoka@tenriyoro.jp

Fig. 1. Histopathology of the lymph node biopsy sample of case 1. (**IA**) H&E stain (original magnification, $\times 10$ objective lens); (**IB**) H&E stain, $\times 40$; (**IC**) anti-CD3 (clone PS1, Novocastra), $\times 20$; (**ID**) anti-CD4 (1F6, Novocastra), $\times 20$; (**IE**) anti-CD8 (M7103, Dako), $\times 20$; (**IF**) anti-CD30 (Ber-H2, Dako), $\times 20$; (**IG**) anti-epithelial membrane antigen (E29, Dako), $\times 20$; (**IH**) anti-ALK (ALK1, Dako), $\times 20$; and (**II**) anti-granzyme B (GrB-7, Merck Millipore), $\times 20$.

CASE REPORT

Case 1

A 39-year-old man presented with progressive back pain and a right inguinal tumor. He had lost 20 kg during the previous month. Computed tomography scans of his body revealed multiple tumors; a soft tissue mass in the posterior mediastinum surrounding the esophagus, a mass in the psoas muscle infiltrating the lumbar spine, and a tumor in the right lung parenchyma; the inguinal tumor was 7 cm in diameter. His hemoglobin level was 13.5 g/dL, white blood cell count $17.0 \times 10^3/\mu\text{L}$ with a marked left shift, and platelet count $263 \times 10^3/\mu\text{L}$. Blood chemistry values were: total protein, 5.8 g/dL; albumin, 2.6 g/dL; lactate dehydrogenase, 171 IU/L; aspartate aminotransferase, 41 IU/L; alanine aminotransferase, 31 IU/L; and alkaline phosphatase, 1,289 IU/L. His serum soluble interleukin-2 level was 24,280 U/mL and C-reactive protein 21.6 mg/dL.

A biopsy specimen of the inguinal node was effaced by cohesive sheets of pleomorphic large cells, and many mitotic figures were detected (Fig. 1). Immunohistochemistry re-

vealed that the tumor cells expressed CD30, epithelial membrane antigen, and cytoplasmic ALK, leading to a diagnosis of ALK⁺ ALCL (Fig. 1). Additional immunohistochemistry included CD3⁺, CD4⁺, CD8⁻, and granzyme B⁺ (Fig. 1), and Epstein-Barr virus-encoded RNAs (EBERs) were negative. The patient was treated with cyclophosphamide, doxorubicin, and vincristine, leading to a transient response. However, he developed a severe pulmonary infection and septicemia due to *Streptococcus oralis*; a bronchoscopic examination showed a tracheoesophageal fistula. The patient died on the 41st hospital day.

Case 2

A 51-year-old man first presented to our institution with left axillary tumors associated with infiltration of the overlying skin and a biopsy sample suggested undifferentiated carcinoma; the patient was treated with regional radiotherapy and the intra-arterial infusion of mitomycin C and doxorubicin. He developed multiple cutaneous tumors of the right lower leg and left thigh eight years after his initial presentation. A biopsy of the skin tumor revealed the diffuse infiltration of

Fig. 2. Histopathology of the cutaneous tumor biopsy specimen of case 2. (2A) H&E stain, $\times 2$ objective lens; (2B) H&E stain, $\times 20$; (2C) anti-CD3, $\times 20$; (2D) anti-CD4, $\times 20$; (2E) anti-CD8, $\times 20$; (2F) anti-CD30, $\times 20$; (2G) anti-epithelial membrane antigen, $\times 20$; (2H) anti-ALK, $\times 20$; and (2I) *in situ* hybridization for EBERS (Epstein-Barr Virus [EBER] PNA Probe/ Fluorescein and DakoCytomation PNA ISH Detection Kit, Dako), $\times 20$.

large cells in the dermis that expressed CD30, epithelial membrane antigen, and cytoplasmic ALK, which finally established a diagnosis of ALK⁺ ALCL (Fig. 2). The lymphoma cells were CD3⁻, CD4⁺, CD8⁻, CD10⁻, and CD20⁻, and EBERS were negative (Fig. 2). A pathological review of the first biopsy specimen by ALK immunohistochemistry confirmed ALK⁺ ALCL of the first tumor. The patient was treated with lymphoma-directing chemotherapy, including CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin), and DHAP (dexamethasone, high-dose cytarabine, and cisplatin), as well as radiotherapy; however, the disease showed multiple relapses involving the skin, subcutaneous tissues, and lymph nodes. He finally developed therapy-related acute myeloid leukemia (t-AML) (Fig. 3) and died of disease progression at the age of 66.

MATERIALS AND METHODS

G-banding

Tumor specimens were aseptically minced to prepare a

cell suspension in culture medium. The cells were incubated overnight at 37°C under a CO₂ concentration of 5%, and then cultured in the presence of 0.1 μ g/mL colcemid for 2 hr. After harvesting, the cells were treated with hypotonic solution and fixed with methanol:acetic acid (3:1). Chromosomes were banded by trypsin-Giemsa staining and the results of chromosome analysis were described according to the ISCN.⁶

Fluorescence in situ hybridization (FISH)

Three FISH probes, namely, the Vysis *ALK* dual-color break-apart probe, Vysis LSI *EGR1/D5S23*, *D5S721* dual-color probe, and Vysis *D7S486/CEP7* FISH probe, were purchased from Abbott Laboratories, Abbott Park, IL, USA. Denaturing of the chromosome/probe, hybridization, and washing conditions were as recommended by the manufacturer. FISH results were analyzed using a fluorescence microscope (Nikon Corporation, Tokyo, Japan) equipped with DAPI, fluorescein isothiocyanate (FITC), and tetramethylrhodamine B isothiocyanate (TRITC) fluorescence filters, as well as a DAPI/FITC/TRITC triple band-pass filter (Nikon

Fig. 3. Bone marrow smear slide of case 2, showing the coexistence of anaplastic large cell lymphoma (ALCL) and therapy-related acute myeloid leukemia (May-Giemsa stain; objective lens, $\times 100$). In 3A, ALCL cells (arrows), leukemic blasts (arrowheads), and a hypogranular neutrophil (asterisk) are shown. In 3B, an ALCL cell and a giant neutrophil are highlighted.

Corporation).

Isolation of RNA

Total RNA was prepared from cryopreserved samples embedded in Tissue-Tek® O. C. T.™ Compound (Sakura Finetek Japan, Tokyo, Japan) using an RNeasy Mini Kit (QIAGEN, Hilden, Germany).

Inverse cDNA PCR

Double-strand cDNA was synthesized from 1 μ g of total RNA using the ALKREVex22-23 primer, 5'-TGGTTGAATTTGCTGATGATC-3', and a cDNA Synthesis Kit (M-MLV Version) (code 6130, Takara Bio, Otsu, Shiga, Japan). The double-strand cDNA was self-ligated by incubating at 12°C for 15 hrs with T4 DNA ligase (code 6022, Takara Bio) in a volume of 20 μ L. The resulting circular cDNA was subjected to nested PCR using primer combinations designed for the known *ALK* sequences in a divergent orientation.⁷ First-round PCR (35 cycles of 94°C for 1 min, 64°C for 1 min, and 72°C for 2 min) was performed with the primers ALKREV3T, 5'-CTGATGGAGGAGGTCTTGCC-3', and ALKFWDex20-21, 5'-ATTCGGGGTCTGGGCCAT-3', in a volume of 20 μ L. One microliter of the 1:100 diluted reaction products from first-round PCR was then subjected to second-round PCR (35 cycles of 94°C for 1 min, 62°C for 1 min, and 72°C for 1 min) with the primers ALKREV4T, 5'-GGTTGTAGTCGGTCATGATGGTC-3', and ALKFWDex21-22, 5'-AGTGGCTGTGAAGACGCTGC-3', in a volume of 20 μ L. The second-round PCR products were visualized by ethidium bromide-stained gel electrophoresis and then directly sequenced in both directions using the pri-

mers ALKFWDex21-22 and ALKREV4T and an ABI 310 automated sequencer (Applied Biosystems, Inc., Foster City, CA).

Reverse transcriptase (RT)-PCR

First-strand cDNA was synthesized from 2 μ g of total RNA in the reaction mixture containing random hexamer primers (Roche Applied Science, Penzberg, Germany) and SuperScript® reverse transcriptase (Invitrogen, Carlsbad, CA). PCR primers and the size of the PCR products were as follows: *ALK* reverse, 5'-CGAGGTGCGGAGCTTGCTCAGC-3', and *ATIC* (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase) forward, 5'-GTGTCCACGGAGATGCAGAG-3', for the *ATIC-ALK* fusion mRNA (315-bp); *ALK* reverse, 5'-AAAGCAGTAGTTGGGGTTGT-3', and *TRAF1* forward, 5'-TGTGGAAGATCACCAATGTC-3', for the *TRAF1-ALK* fusion mRNA (196-bp); and *ALK*-III-R, 5'-GTTGGGCCTGTCTTCAGGCTGATGTTGC-3', and *ALK*-III-F, 5'-GGGCCATGGCGCCTTTGGGGAGGT-3', for the tyrosine kinase domain of *ALK* (760 bp).^{5,8,9}

RESULTS

G-banding and FISH

Case 1: Cytogenetic specimens were prepared from the inguinal lymph node biopsy. G-banding showed a complex karyotype of tetraploidy or octaploidy. FISH using the Vysis *ALK* dual-color break-apart probe to the metaphase spreads revealed multiple copies of a submetacentric marker chromosome labeled solely by the red signal representing 3' *ALK*, in

Fig. 4. G-banded karyotype obtained from the biopsy sample. (**4A**) The partial karyotype of case 2, showing three copies of chromosome 2 and 10 copies of the submetacentric marker chromosome. The metaphase spread of this karyotype is shown in Fig. 5, top. (**4B**) The complete karyotype of case 2. The gain or loss of chromosomes and structural abnormalities are indicated by arrows. The karyotype according to the ISCN was: 46,X,-Y,+ add(2)(p1?3),del(4)(p15),add(5)(q31),add(7)(p14),del(8)(q23),+ 9,der(11)t(11;18)(q25;q11),add(12)(q24),-18,-20,+ mar[10].

addition to normal chromosome 2 labeled by both the red and the green (representing 5' *ALK*) signals on 2p23 (Fig. 4A & 5, top). These results suggest that the rearrangement may have occurred within the *ALK* gene locus and the rearranged gene was amplified. However, karyotyping was not completed due to the complexity.

Case 2: A lymph node biopsy specimen obtained on relapse was subjected to cytogenetic and FISH studies. G-banding revealed multiple numerical and structural abnormalities, including a der(2) [add(2)(p1?3)] and der(5) [add(5)(q31)] chromosome (Fig. 4B). FISH using the *ALK* break-apart probe showed that the 5' *ALK* green signal was localized on the long arm of der(5) and the 3' *ALK* red signal was on the end of the long arm of chromosome 12; the der(2) chromosome had lost the *ALK* signal (Fig. 5, middle).

On examination of the bone marrow smear slide at the time of the development of t-AML, ALCL tumor cells comprised 3.7% of the nucleated cells (Fig. 3). G-banding revealed metaphase spreads of hypodiploid and tetraploid karyotypes. The former karyotype represented the t-AML clone, carrying del(5q) and del(7q), both of which were confirmed by FISH using each probe (Supplementary Fig. S1 & S2); the

del(7q)-carrying cells comprised 88.0% of the nucleated cells. On the other hand, the tetraploid karyotype included marker chromosomes identical to those identified in the karyotype of the lymph node biopsy specimen, which was consistent with bone marrow infiltration by ALCL. *ALK*-FISH applied to the tetraploid metaphases confirmed two copies of der(5) labeled by the 5' *ALK* green signal and two copies of chromosome 12 labeled by the 3' *ALK* red signal (Fig. 5, bottom). Additional FISH using the Vysis LSI *EGR1*/D5S23, D5S721 dual-color probe, which was designed to detect del(5q), showed that the short arm of der(2) contained the *EGR1* locus normally localized on 5q31, indicating that chromosomal materials including *ALK* on 2p23 and *EGR1* on 5q31 had been reciprocally exchanged (Supplementary Fig. S3), presumably unrelated to the *ALK* rearrangement.

Identification of translocation partners of *ALK*

The cytoplasm-only *ALK* positivity on immunohistochemistry and absence of t(2;5)(p23;q35) on metaphase FISH analysis suggested that ALCL of the present two cases carried variant *ALK* translocations.^{1,2,10} We employed an inverse

Fig. 5. Fluorescence *in situ* hybridization (FISH) using the Vysis *ALK* dual-color break-apart probe. The probe consisted of a red signal representing 3' *ALK* and a green signal representing 5' *ALK*. *Top*, a metaphase spread of octaploidy obtained from the lymph node biopsy sample of case 1. Pictures with DAPI, FITC, and TRITC fluorescence filters are arranged from *left to right*. Submetacentric marker chromosomes labeled solely by a red signal are indicated by *closed arrows* and normal chromosome 2 labeled by both red and green signals is indicated by *open arrows*. G-banded pictures of these chromosomes are shown in Fig. 4A. *Middle*, G-banding, FITC, and TRITC pictures of a metaphase spread obtained from the lymph node biopsy specimen of case 2. Red signals localized on chromosomes 2 and 12, and green signals on chromosomes 2 and der(5) [add(5)(q31)] are shown with *arrows* of each respective color. The der(2) [add(2)(p1?3)] chromosome lacked the *ALK* signal (*white arrows*). Additional FISH showed that the *c-MYC*, which normally localized on 8q24, had been translocated to the end of the long arm of der(5) (data not shown). *Bottom*, G-banding and triple band-pass filter pictures of a tetraploid metaphase spread obtained from the bone marrow aspirates of case 2, showing red signals on the two copies of chromosome 12 and green signals on the two copies of der(5). Two copies of chromosome 2 were labeled by the *ALK* fusion signal (*yellow*), while two copies of der(2) lacked *ALK*.

Fig. 6. Amplification and sequencing of *ATIC-ALK* (case 1) and *TRAF1-ALK* (case 2) fusion mRNAs. **(6A)** Ethidium bromide-stained gel electrophoresis of inverse cDNA polymerase chain reaction (PCR) products. Direct sequencing of the products (*horizontal arrows*) revealed the sequences of the *ATIC* and *TRAF1* genes following *ALK* (Supplementary Fig. S4). Lane M, 100-bp ladder as a molecular weight marker. **(6B)** Ethidium bromide-stained gel electrophoresis of reverse transcriptase polymerase chain reaction (RT-PCR) of the *ATIC-ALK* and *TRAF1-ALK* fusion mRNAs. RT-PCR corresponding to the tyrosine kinase domain of *ALK* (*ALK-TK*) and *ACTIN* is shown at the bottom.^{9,19} Karpas 299, an ALCL cell line with t(2;5)(p23;q35); CML cells, chronic myeloid leukemia cells as a negative control. **(6C)** Nucleotide and deduced amino acid (*one-letter code*) sequences adjacent to the *ATIC-ALK* and *TRAF1-ALK* junctions (*vertical arrows*). The valine residue (*bold*) was encoded by the codon encompassing the junction.

cDNA PCR strategy to identify the partner of *ALK*.⁷ As shown in Fig. 6A, single species of PCR products of approximately 0.6 and 0.5 kb in size were successfully amplified. Nucleotide sequencing of the PCR products and a database search revealed that the sequences of *ATIC* in case 1 and *TRAF1* in case 2 appeared to follow that of *ALK* (Supplementary Fig. S4 & S5). We subsequently confirmed *ATIC-ALK* and *TRAF1-ALK* fusion mRNA by conventional RT-PCR using a primer combination designed for each gene (Figure 6B).⁵ Nucleotide sequencing of the RT-PCR products determined that exon 7 of *ATIC* and exon 6 of *TRAF1* had fused in frame to exon 20 of *ALK*, encoding the *ATIC-ALK* and *TRAF1-ALK* chimeric protein (Fig. 6C).

DISCUSSION

We described the clinical, histopathological, and cytogenetic findings of two cases of *ALK*⁺ ALCL, showing “cytoplasm-only” *ALK* immunopositivity. FISH using an *ALK* break-apart probe demonstrated the rearrangement of *ALK*, while the rearrangement did not represent the most common translocation, t(2;5)(p23;q35), but suggested a variant translocation in each case. We finally determined that the genes encoding *ATIC* and *TRAF1* were the partners of *ALK* using an inverse cDNA PCR strategy.

The *ATIC-ALK* fusion mRNA was first identified by means of the 5' RACE protocol,⁴ in which an anchor sequence is added to the 5' end of the cDNA, followed by a series of

hemi-nested anchored PCRs. In principle, as only one gene-specific primer is used, 5' RACE often generates a high level of nonspecific amplification. On the other hand, we previously performed inverse PCR from genomic DNA templates to identify partner genes of *BCL6* in B-cell tumors, leading to the isolation of a variety of non-immunoglobulin gene partners of *BCL6*.¹¹ In the current study, we applied the inverse PCR strategy for cDNA synthesized from mRNA that theoretically contained the sequence of an unknown partner. In contrast to 5' RACE, as the nested PCR primer pairs were specifically designed for the known sequence of *ALK*, we successfully obtained the amplification products that were readily identifiable on ethidium bromide-stained gel electrophoresis (Fig. 6A).

ATIC is the second most common partner gene of variant *ALK* rearrangements.² The *ATIC-ALK* fusion was previously shown to be generated by the pericentric inversion of chromosome 2 at the breakpoints of p23 and q35 [inv(2)(p23q35)], in which the *ALK* and *ATIC* genes are localized, respectively.^{8,12} However, in case 1, inv(2)(p23;q35) was not recognized by either G-banding or metaphase FISH analysis. Since the inv(2)(p23q35) chromosome was reported to be affected by a secondary structural abnormality by us and others,^{12,13} chromosomal segments containing the reciprocal *ALK-ATIC* fusion, which was labeled by the 5' *ALK*-green signal, were most likely deleted. This generated the submetacentric marker chromosome, which theoretically contained the *ATIC-ALK* fusion gene alone; the marker chromosome may be designated as der(2)inv(2)(p23q35)del(2)(p?21) by ISCN (Fig. 4A).⁶ An increase in the copy number of the *ATIC-ALK* fusion gene may have enhanced the expression of chimeric proteins, potentially contributing to the aggressive clinical behavior of this particular case.

The *TRAF1-ALK* fusion gene was first reported by Feldman *et al.* in 2013,⁵ and case 2 is the second reported case of ALK⁺ ALCL carrying this particular fusion gene. The chromosomal locus of the *TRAF1* gene has been mapped at 9q33-34.¹⁴ Thus, owing to similarities to the *NPM-ALK* generated by t(2;5)(p23;q35), the *TRAF1-ALK* fusion gene is predicted to be generated by t(2;9)(p23;q33-34) chromosomal translocation. However, no chromosomal abnormality was visible in the three copies of chromosome 9, and chromosome 12, in which 3' *ALK* was located by FISH and the *TRAF1-ALK* fusion gene was theoretically localized, was cytogenetically normal (Fig. 4B). As the locus of *TRAF1* is close to the telomeric end of the long arm of chromosome 9, the chromosomal materials involved in translocation may have been too small to be identified under a microscope. On the other hand, it currently remains unknown whether 5' *ALK* on der(5) represented reciprocal *ALK-TRAF1* fusion. Unfortunately, we were unable to verify the fusion gene at the cytogenetic level because chromosomal specimens were no longer available.

TRAF proteins mediate the transduction of signals from

various receptors of the TNF receptor superfamily. TRAF1 in association with TRAF2 forms a heterodimeric complex, which is required for the TNF α -mediated activation of MAPK8/JNK and NF- κ B.^{15,16} The theoretical TRAF1-ALK chimeric protein, in the N-terminus toward a C-terminus orientation, is composed of the coiled-coil domain of TRAF1, truncating the MATH/TRAF1 domain that binds to the receptor cytoplasmic domain, and the intracellular tyrosine kinase domain of ALK (Supplementary Fig. S5). As the TRAF1 coiled-coil domain mediates homo- and hetero-oligomerization, the TRAF1-ALK chimeric protein appears to undergo homodimerization in the cytoplasm, similar to other non-nuclear ALK fusion chimera,³ thereby enhancing ALK kinase activity.

ALK⁺ ALCL most frequently occurs in the first three decades of life.² In reflection of this younger age distribution, the rate of a complete response following first-line chemotherapy was reported to be 86%, and the progression-free and overall survival rates at 8 years were as high as 72% and 82%, respectively.¹⁷ It remains to be clarified whether the clinical features and treatment outcomes of ALK⁺ ALCL with variant *ALK* rearrangements are similar to those of the majority of cases with t(2;5)(p23;q35)/*NPM-ALK*. In the Japanese literature, Matsubara *et al.* reported a pediatric case having the *ATIC-ALK* fusion gene, in which the disease corresponded to the standard risk category and responded well to ALCL 99 chemotherapy.¹⁸ In contrast, we previously reported an elderly patient with inv(2)(p23q35)/*ATIC-ALK*-carrying ALK⁺ ALCL who had disseminated disease at presentation and showed a rapidly deteriorating clinical course,¹³ similar to case 1 described herein. However, in case 2, the patient with *TRAF1-ALK* developed the disease in the fifth decade of life, and showed multiple relapses 8 years after the initial treatment in spite of intensive chemoradiotherapies. These features are common with those of Feldman's case, in which the patient developed ALK⁺ ALCL at the age of 41, relapsed after a long-term complete response induced by initial CHOP chemotherapy, and finally underwent salvage chemotherapies including high-dose therapy with autologous stem-cell transplantation.⁵ Thus, it is possible that the *TRAF1-ALK* fusion gene may define a unique subset within ALK⁺ ALCL, which preferentially develops in older individuals and shows multiple relapses. Further studies are required to determine whether individual variant translocations/inversions in ALK⁺ ALCL are related to particular clinical features and treatment outcomes.

REFERENCES

- Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, *et al.*: CD30⁺ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. *Blood* 96:3681-3695, 2000
- Delsol G, Jaffe ES, Falini B, Gascoyne RD, Müller-Hermelink

- HK, *et al.*: Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, *et al.* (eds): World Health Organization Classification of Tumours, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, International Agency for Research on Cancer (IARC), pp.312-316, 2008
- 3 Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer* 8:11-23, 2008
- 4 Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, *et al.*: A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. *Cancer Res* 60:793-798, 2000
- 5 Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, *et al.*: Novel *TRAF1-ALK* fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. *Genes Chromosomes Cancer* 52:1097-1102, 2013
- 6 ISCN (2009): An International System for Human Cytogenetic Nomenclature (2009). Basel, S. Karger, 2009
- 7 Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, *et al.*: KIF5B-ALK, a novel fusion oncokine identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res* 15:3143-3149, 2009
- 8 Ma Z, Cools J, Marynen P, Cui X, Siebert R, *et al.*: Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. *Blood* 95:2144-2149, 2000
- 9 Dirks WG, Fährnich S, Lis Y, Becker E, MacLeod RA, *et al.*: Expression and functional analysis of the anaplastic lymphoma kinase (*ALK*) gene in tumor cell lines. *Int J Cancer* 100:49-56, 2002
- 10 Allouche M: ALK (anaplastic lymphoma receptor tyrosine kinase). *Atlas Genet Cytogenet Oncol Haematol*. February 2010. URL: <http://AtlasGeneticsOncology.org/Genes/ALK.html>, 2010
- 11 Akasaka H, Akasaka T, Kurata M, Ueda C, Shimizu A, *et al.*: Molecular anatomy of *BCL6* translocations revealed by long-distance polymerase chain reaction-based assays. *Cancer Res* 60:2335-2341, 2000
- 12 Wlodarska I, De Wolf-Peeters C, Falini B, Verhoef G, Morris SW, *et al.*: The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. *Blood* 92:2688-2695, 1998
- 13 Okamori S, Maesako Y, Ehara J, Fujita K, Takeoka K, *et al.*: An elderly man with anaplastic large cell lymphoma carrying inv(2)(p23q35) who presented with cardiopulmonary failure: Clinical, pathological, and cytogenetic features and postmortem findings. *Tenri Medical Bulletin* 16:89-100, 2013
- 14 TRAF1 TNF receptor-associated factor 1 [*Homo sapiens* (human)]. Available at: <http://www.ncbi.nlm.nih.gov/gene/7185>
- 15 Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. *Cell* 78:681-692, 1994
- 16 Chung JY, Park YC, Ye H, Wu H: All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. *J Cell Sci* 115:679-688, 2002
- 17 Sibon D, Fournier M, Briere J, Lamant L, Haioun C, *et al.*: Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. *J Clin Oncol* 30:3939-3946, 2012
- 18 Matsubara K, Tanaka T, Taki T, Nakagawa A, Nigami H, *et al.*: *ATIC-ALK*-positive anaplastic large cell lymphoma: a case report and review of the literature. *Rinsho Ketsueki* 49:325-330, 2008 (*in Japanese*)
- 19 Maesako Y, Izumi K, Okamori S, Takeoka K, Kishimori C, *et al.*: inv(2)(p23q13)/RAN-binding protein 2 (*RANBP2*)-*ALK* fusion gene in myeloid leukemia that developed in an elderly woman. *Int J Hematol* 99:202-207, 2014

Supplementary Figures

Fig. S1. G-banded karyotype of the t-AML clone of case 2. Numerical and structural abnormalities are indicated by arrows. The karyotype was: 44,XY,del(5)(q13q31),der(7;17)(p10;q10),-18[1]/43,idem,-20[7].

Fig. S2. Fluorescence *in situ* hybridization confirming del(5q) (top) and del(7q) (bottom) in hypodiploid metaphases representing the t-AML clone of case 2. Arrows indicate the del(5)(q13q31) and der(7;17)(p10;q10) chromosomes. The probes used were the Vysis LSI *EGR1*/D5S23, D5S721 dual color probe for del(5q) and Vysis D7S486/CEP7 FISH probe for del(7q).

Fig. S3. A G-banded metaphase spread of the tetraploid karyotype of case 2 (left) and FISH using the Vysis LSI *EGR1*/D5S23, D5S721 dual color probe (right). The *EGR1* locus on 5q31 represented by the red signal was translocated to the two der(2) [add(2)(p1?3)] chromosomes (red arrows). Two copies of normal chromosome 5 and the der(5) [add(5)(q31)] chromosome are indicated by yellow and green arrows, respectively.

Fig. S4. Nucleotide sequences of the inverse cDNA product, representing the sequences of *ALK* and *AT1C* (case 1) and *ALK* and *TRAF1* (case 2). The sequencing primer used was ALKREV4T.

Fig. S5. Schematic diagram of the TRAF1-ALK chimeric protein.